Denied Humira? You Still Have Options.
Humira (adalimumab) is one of the most widely prescribed biologics in the world, used for rheumatoid arthritis, Crohn's disease, psoriasis, and several other conditions — and yet denials happen. With the arrival of biosimilar versions of adalimumab, many insurance formularies have shifted away from Humira and now require biosimilar step therapy first. You may also face a denial if your prior authorization wasn't filed correctly or if your plan has formulary-level restrictions favoring one of the newer adalimumab biosimilars.
Option 1: Appeal Your Denial
If your doctor prescribed brand Humira specifically — or if you've already had a response to Humira that you'd lose by switching — that clinical reasoning belongs in your appeal. A strong letter of medical necessity explaining why brand adalimumab is the appropriate choice can make the difference. Ellen can help you draft your appeal letter.
Option 2: Explore Clinical Trials
Adalimumab and anti-TNF therapies broadly are well-studied, and clinical trials continue for many of the conditions Humira treats. You may find trials studying biosimilar adalimumab formulations, combination therapies, or next-generation approaches for your specific condition. Check ClinicalTrials.gov using your diagnosis — rheumatoid arthritis, Crohn's disease, ankylosing spondylitis, or others — to see what's currently available.
Option 3: Patient Assistance Programs
AbbVie, Humira's manufacturer, offers the myAbbVie Assist program, which provides free medication to eligible individuals who meet income and insurance requirements. The Arthritis Foundation (arthritis.org) and the Crohn's and Colitis Foundation (crohnscolitisfoundation.org) also connect people to financial assistance resources.
For a complete guide to Humira financial assistance — including copay cards, free drug programs, and independent foundations — see our financial assistance page for Humira.
Ellen can help you figure out your next step. Start with Ellen →
Frequently Asked Questions
Why was Humira denied?
With multiple biosimilar versions of adalimumab now on the market, many insurance plans have redesigned their formularies to prefer biosimilars over brand Humira — it's a cost-driven decision. Your denial may reflect a formulary exclusion of brand Humira, a requirement to try a biosimilar first, or a prior authorization gap. If you're a new patient, you may also face step therapy requirements that require trying less expensive therapies first. Your denial letter will explain which of these applies.
Can I get Humira through a clinical trial?
Clinical trials for adalimumab are less common now that the drug is well-established, but trials do exist for its biosimilars and for newer therapies in the anti-TNF class. More commonly, you might find trials for your underlying condition that use next-generation biologics as the study drug. If a trial provides a similar mechanism of action for your condition, it may be worth exploring with your doctor. Search ClinicalTrials.gov for current options.
How long does a Humira appeal take?
For a standard, non-urgent appeal, your insurer generally has 30 days to make a decision. If the situation is medically urgent, that window shrinks to 72 hours. If your initial appeal is denied, you can pursue an independent external review — that process usually takes up to 45 days. Keep copies of everything you submit, and note every deadline carefully. Talk to your doctor before making any decisions about your treatment.